ES2772930T3 - Prohormona arginina vasopresina como biomarcador predictivo para la diabetes - Google Patents

Prohormona arginina vasopresina como biomarcador predictivo para la diabetes Download PDF

Info

Publication number
ES2772930T3
ES2772930T3 ES16205552T ES16205552T ES2772930T3 ES 2772930 T3 ES2772930 T3 ES 2772930T3 ES 16205552 T ES16205552 T ES 16205552T ES 16205552 T ES16205552 T ES 16205552T ES 2772930 T3 ES2772930 T3 ES 2772930T3
Authority
ES
Spain
Prior art keywords
diabetes
copeptin
assay
subjects
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16205552T
Other languages
English (en)
Spanish (es)
Inventor
Joachim Struck
Andreas Bergmann
Olle Melander
Christopher Newton-Cheh
Thomas J Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
General Hospital Corp
Original Assignee
BRAHMS GmbH
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAHMS GmbH, General Hospital Corp filed Critical BRAHMS GmbH
Application granted granted Critical
Publication of ES2772930T3 publication Critical patent/ES2772930T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G01N2410/04—Oxytocins; Vasopressins; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES16205552T 2008-10-31 2009-10-29 Prohormona arginina vasopresina como biomarcador predictivo para la diabetes Active ES2772930T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168096 2008-10-31

Publications (1)

Publication Number Publication Date
ES2772930T3 true ES2772930T3 (es) 2020-07-08

Family

ID=40445457

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16205552T Active ES2772930T3 (es) 2008-10-31 2009-10-29 Prohormona arginina vasopresina como biomarcador predictivo para la diabetes
ES09744978.9T Active ES2645688T3 (es) 2008-10-31 2009-10-29 Prohormona arginina-vasopresina como biomarcador predictivo de la diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09744978.9T Active ES2645688T3 (es) 2008-10-31 2009-10-29 Prohormona arginina-vasopresina como biomarcador predictivo de la diabetes

Country Status (7)

Country Link
US (2) US9116153B2 (enExample)
EP (2) EP3199951B1 (enExample)
JP (2) JP5785086B2 (enExample)
CN (3) CN102317788A (enExample)
DK (1) DK3199951T3 (enExample)
ES (2) ES2772930T3 (enExample)
WO (1) WO2010049179A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
AU2007233320B2 (en) 2006-04-04 2013-12-12 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
US20130149386A1 (en) * 2011-12-07 2013-06-13 Region Nordjylland Cd36 as biomarker for steatosis
WO2013188605A2 (en) * 2012-06-15 2013-12-19 Nuclea Biotechnologies, Inc. Predictive markers for cancer and metabolic syndrome
JP6196034B2 (ja) 2012-12-20 2017-09-13 ライオン株式会社 高血糖リスク判定用マーカーペプチドおよびその用途
CN103266089A (zh) * 2013-05-09 2013-08-28 南京医科大学第一附属医院 抗人和肽素单克隆抗体mcco1及其应用
EP3002589A1 (en) * 2014-10-01 2016-04-06 sphingotec GmbH A method for stratifying a female subject for hormone replacement therapy
MX2021011807A (es) * 2019-03-28 2021-10-26 Lundoch Diagnostics AB Uso de follistatina en la prediccion del riesgo de diabetes tipo 2.
CN113238063A (zh) * 2021-05-31 2021-08-10 迈克生物股份有限公司 Gdf15评估代谢综合征患者进展为心血管疾病的应用
CN113248590B (zh) * 2021-06-24 2021-09-10 天津奇云诺德生物医学有限公司 一种NT-proBNP蛋白抗原决定簇多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
WO2004006860A2 (en) * 2002-07-16 2004-01-22 Woomera Therapeutics, Inc. Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
CA2537668A1 (en) * 2003-09-29 2005-04-14 Biosite Incorporated Methods and compositions for the diagnosis of sepsis
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
CN101326439A (zh) * 2005-10-11 2008-12-17 特提斯生物科学公司 糖尿病相关标记及其应用方法
US9285362B2 (en) * 2006-10-18 2016-03-15 Axela, Inc. Measuring multiple analytes over a broad range of concentrations using optical diffraction
DE112007003185A5 (de) * 2006-10-26 2009-10-01 Brahms Aktiengesellschaft Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
WO2008128352A1 (en) * 2007-04-19 2008-10-30 Axela, Inc. Methods and compositions for signal amplification

Also Published As

Publication number Publication date
CN103713137A (zh) 2014-04-09
US9952229B2 (en) 2018-04-24
JP2015135338A (ja) 2015-07-27
US9116153B2 (en) 2015-08-25
ES2645688T3 (es) 2017-12-07
EP2356463B1 (en) 2017-08-30
US20150293127A1 (en) 2015-10-15
EP2356463A1 (en) 2011-08-17
DK3199951T3 (da) 2020-02-24
WO2010049179A1 (en) 2010-05-06
JP2012507020A (ja) 2012-03-22
CN106153943B (zh) 2019-02-15
CN106153943A (zh) 2016-11-23
JP5785086B2 (ja) 2015-09-24
US20110318766A1 (en) 2011-12-29
CN102317788A (zh) 2012-01-11
JP6055005B2 (ja) 2016-12-27
EP3199951B1 (en) 2019-11-20
EP3199951A1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
ES2772930T3 (es) Prohormona arginina vasopresina como biomarcador predictivo para la diabetes
ES2618077T3 (es) Biomarcadores de pronóstico para la progresión de la enfermedad renal crónica primaria
ES2431358T3 (es) Pronóstico y evaluación del riesgo en pacientes que padecen insuficiencia cardíaca mediante la determinación de la concentración de ADM
ES2795003T3 (es) Biomarcador para la predicción de los primeros eventos adversos
Yip et al. Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke
DK2470910T3 (en) Procalcitonin for the prognosis of side effects
CN102203608B (zh) 用于与代谢综合征、心血管疾病和/或胰岛素抗性相关的病症的诊断、预后、监测和治疗追踪的体外方法
EP3286570A1 (en) A method for predicting the risk of incidence of chronic kidney disease
US20060183174A1 (en) Diagnosis
HK1194816A (en) Arginine vasopressin pro-hormone as predictive biomarker for diabetes
HK1163812A (en) Arginine vasopressin pro-hormone as predictive biomarker for diabetes
HK1203611B (en) Prognosis of adverse events in patients with suspected chronic heart failure
HK1203611A1 (en) Prognosis of adverse events in patients with suspected chronic heart failure
HK1163813B (en) Use of adm in manufacturing an agent for evaluating heart failure and/or shortness of breath
WO2010018123A1 (en) Retinol binding protein 4 as a marker of peripheral insulin resistance in type 1 diabetes